Over the past few years, as the understanding of m6A modification has advanced, it has been reported that m6A is involved in drug resistance in various solid tumours, including liver cancer, colon cancer, and gastric cancer [10–12].However, the relationship between METTL3-mediated m6A methylation and chemoresistance in SCLC has not been explored. The gene discussed is METTL3; the disease is small cell lung carcinoma.